Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vaxart Inc (VXRT)

Vaxart Inc (VXRT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 998,106
  • Shares Outstanding, K 109,202
  • Annual Sales, $ 9,860 K
  • Annual Income, $ -18,650 K
  • 60-Month Beta 0.29
  • Price/Sales 100.65
  • Price/Cash Flow N/A
  • Price/Book 24.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate -0.04
  • Low Estimate -0.11
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +71.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.45 +8.17%
on 08/03/20
17.15 -46.71%
on 07/16/20
-7.83 (-46.14%)
since 07/14/20
3-Month
2.23 +309.87%
on 06/09/20
17.49 -47.74%
on 07/14/20
+6.13 (+203.65%)
since 05/14/20
52-Week
0.25 +3,494.18%
on 09/25/19
17.49 -47.74%
on 07/14/20
+8.48 (+1,274.44%)
since 08/14/19

Most Recent Stories

More News
These Are Some of The Top Companies Racing to Develop a Pandemic Treatment

The CV-19 pandemic shows no signs of slowing. To date, there are nearly 21 million cases, with 769,235 ...

RVVTF : 0.2295 (+9.91%)
MRNA : 69.15 (+1.95%)
JNJ : 148.24 (+0.16%)
VXRT : 9.14 (+0.55%)
CYDY : 3.7599 (-6.00%)
RVV.CN : 0.300 (+7.14%)
Moore Kuehn, PLLC Encourages Investors of GWRE, VXRT, or FE to Contact Law Firm

, /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related...

GWRE : 110.63 (+1.78%)
VXRT : 9.14 (+0.55%)
FE : 29.33 (-0.91%)
Investor Alert: Ademi & O'Reilly, LLP Investigates Possible Securities Fraud of Vaxart, Inc.

, /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating possible securities fraud claims against Vaxart (Nasdaq: VXRT) resulting from inaccurate statements Vaxart made regarding its internal controls,...

VXRT : 9.14 (+0.55%)
Patient Monitoring Capabilities Expand Treatment Possibilities

, /PRNewswire/ -- The patient monitoring device market is a large and diverse segment of the medical device industry. Traditionally, patient monitoring devices were used in hospitals to monitor patient's...

HTBX : 1.6700 (-8.74%)
INOTF : 0.0270 (+14.89%)
NVAX : 146.51 (+9.93%)
VXRT : 9.14 (+0.55%)
NMRD : 5.54 (-2.46%)
PHG : 52.21 (-1.08%)
Coronavirus Vaccine Efforts Key to Vaxart (VXRT) Q2 Earnings

Vaxart (VXRT) has been working on developing a coronavirus vaccine. Increased clinical activity is expected to have increased expenses.

JNJ : 148.24 (+0.16%)
GSK : 40.55 (-1.55%)
EBS : 133.42 (-1.13%)
VXRT : 9.14 (+0.55%)
4 Coronavirus Vaccine Stocks With Insider Selling

Companies working on a coronavirus vaccine have seen insane gains. So, it's interesting to note the high levels of insider selling in some of these companies. REGN, MRNA, QDEL, and VXRT are stocks in which...

REGN : 612.57 (+0.28%)
MRNA : 69.15 (+1.95%)
QDEL : 245.93 (-1.38%)
VXRT : 9.14 (+0.55%)
4 Best-Performing Small-cap Biotechnology Stocks

Biotech stocks have been one of the strongest sectors since the coronavirus started impacting financial markets.  Here are 4 of the best-performing small-cap biotech stocks in 2020. Biotech stocks...

AKBA : 10.53 (-0.94%)
IBB : 133.36 (-0.48%)
MRSN : 18.58 (+1.59%)
VXRT : 9.14 (+0.55%)
TRIL : 8.75 (-1.80%)
Emergent (EBS) Beats Q2 Earnings Estimates, Ups '20 Guidance

Emergent's (EBS) second-quarter earnings beat estimates on robust product sales. Concurrently, it increases its annual guidance.

JNJ : 148.24 (+0.16%)
AZN : 55.19 (-1.09%)
EBS : 133.42 (-1.13%)
VXRT : 9.14 (+0.55%)
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?

Vaxart (VXRT) has been actively engaged in developing a coronavirus vaccine. Investors are likely to focus on progress of vaccine program on the Q2 earnings call.

JNJ : 148.24 (+0.16%)
INCY : 94.87 (-0.72%)
GSK : 40.55 (-1.55%)
VXRT : 9.14 (+0.55%)
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors with Significant Losses and Persons Who May Assist Firm's Investigation of Possible Securities Fraud to Contact Its Attorneys Now

, /PRNewswire/ -- Hagens Berman urges Vaxart, Inc. (NASDAQ: VXRT) investors who have suffered significant losses to .  Hagens Berman also encourages persons who may be able to assist the Firm's investigation...

VXRT : 9.14 (+0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade VXRT with:

Business Summary

Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The company's vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate risk of needle-stick...

See More

Key Turning Points

2nd Resistance Point 9.74
1st Resistance Point 9.44
Last Price 9.14
1st Support Level 8.94
2nd Support Level 8.74

See More

52-Week High 17.49
Fibonacci 61.8% 10.91
Last Price 9.14
Fibonacci 50% 8.87
Fibonacci 38.2% 6.84
52-Week Low 0.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar